Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good chance to see today or AH $5.00 finnaly
It already 4.50 on pre-market, charts are Overbought Bullish-strong combination
I have no doubt :)
thats too bad
I didn't know that FDA can be late with desicion if they first point 90 days, well that is already late since august
You right got excited too quickly
7:15 trading at $6.00 now 7:45 its only $4.75? what a jump
OXGN- will run today ,awsome NEWS!!!
OXiGENE Reports Further Positive Safety and Efficacy Data From Ongoing Phase 2 Trial of ZYBRESTAT in Non-Small Cell Lung Cancer
Nov 19, 2010 2:00:00 AM
2010 GlobeNewswire, Inc.
Close Ad
Email story | Discuss on ZenoBank | View more ads SOUTH SAN FRANCISCO, Calif., Nov. 19, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT(TM) (CA4P) in patients with non-small cell lung cancer (NSCLC). The updated analysis showed that the median time to progression for patients receiving ZYBRESTAT plus bevacizumab and chemotherapy was 9.5 months, compared with a median time to progression of 8.8 months for patients receiving bevacizumab and chemotherapy alone. Of the patients in the study arm (ZYBRESTAT combined with bevacizumab and carboplatin/paclitaxel chemotherapy), 50% achieved a partial response, compared with the control arm (bevacizumab and chemotherapy) of the trial, where only 38% of patients achieved a partial response. The combination regimen including ZYBRESTAT was observed to be well-tolerated with no significant cumulative toxicities when compared with the control arm of the study.
The data were presented in a poster session at the 22nd EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics" in Berlin, Germany. The poster was titled, " Randomized Phase 2 Trial of a Vascular Disrupting Agent (VDA) Fosbretabulin Tromethamine (CA4P) with Carboplatin, Paclitaxel and Bevacizumab in Stage IIIB/IV Non-Squamous Non Small Cell Lung Cancer (NSCLC): Analyses of Safety and Efficacy," by Edward Garon, M.D., Assistant Professor of Medicine at the University of California, Los Angeles and principal investigator of the study.
"The FALCON study interim data continues to be encouraging, suggesting that ZYBRESTAT is a well-tolerated drug that has the potential to result in better patient outcomes than standard therapy," commented Dr. Garon. "This updated data provides additional support for a possible registration study investigating ZYBRESTAT as a treatment for patients with NSCLC."
"The results from the FALCON study continue to show that ZYBRESTAT appears well-tolerated and suggest improved progression free survival and response rate in NSCLC patients," commented Peter Langecker, M.D., Chief Executive Officer at OXiGENE. "While these data must accrue for several more months before we can truly analyze the overall survival benefit to patients, we believe that the continued trends of the FALCON study, which come on the heels of our positive data from a study of patients with anaplastic thyroid cancer, shows that ZYBRESTAT may hold promise as a future treatment for cancer patients."
FALCON is a randomized controlled study investigating the addition of ZYBRESTAT (fosbretabulin tromethamine, or CA4P) to standard therapy (carboplatin, paclitaxel, and bevacizumab) in patients with Stage IIIb or IV non-squamous NSCLC. A total of 60 patients were treated with study medication, including 29 in the standard therapy arm and 31 in the CA4P + standard therapy arm. The treatment arms were well balanced with respect to baseline characteristics, except for a greater percentage of males in the CA4P arm. Disease was predominately Stage IV in both arms. Patients received CA4P plus standard therapy or standard therapy alone every 21 days for up to 6 cycles (treatment phase). Patients without disease progression after 6 cycles could continue to receive bevacizumab with or without CA4P (depending on treatment arm) until disease progression (maintenance phase).
Key data points from the ongoing FALCON trial are as follows.
Progression-free survival (PFS)
•PFS determined by RECIST criteria
•Median PFS was 9.5 months in the CA4P arm versus 8.8 months in the standard therapy arm (hazard ratio (95%CI) = 0.73 (0.33, 1.62))
•PFS represents a 27% reduction in the odds of progression for patients receiving CA4P vs. standard therapy
Best Overall Tumor response
•Partial Response (PR) was 50% in the CA4P arm and 38% in the standard therapy arm
A copy of the EORTC-NCI-AACR presentations will be available on OXiGENE's website at www.oxigene.com.
About ZYBRESTAT (fosbretabulin)
ZYBRESTAT is being evaluated in a Phase 2 study of patients with non-small cell lung cancer and other clinical trials. OXiGENE believes that ZYBRESTAT is poised to become an important product in a novel class of small-molecule drug candidates called vascular disrupting agents. Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. In clinical trials in solid tumors, ZYBRESTAT has demonstrated potent and selective activity against tumor vasculature, as well as clinical activity against anaplastic thyroid cancer, ovarian cancer and various other solid tumors.
About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969
Safe Harbor Statement
This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include projected study outcomes, emerging oncology treatments and the expected conclusion of ongoing or initiation of new clinical studies may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the outcome of clinical studies and the availability of additional financing to continue development of ZYBRESTAT.
Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2009.
CONTACT: OXiGENE, Inc.
Investor and Media Contact:
Michelle Edwards, Investor Relations
650-635-7006
medwards@oxigene.com
MELA is approved!! trading over $6.00 alrady and its only 7:15 AM
Awsome, next is EDAP
testing lower BB on 60 min charts should hold 3.95-98
FDA must give a desicion this - latest next week, other-wise it is more then 90 days since august
Absolutely agree. If CEO will not dump us with some unusuall PR about SS changes and will stick with the company Plan you can be sure that this Stock will rise on Value at least 10 times what is now. Thats why I stay with this one untill any words from the company and I thing MM's doing the same otherwise this would be trading now around .0010-15
Good luck
CGFIA is really on of the rarest stocks on OTCBB to hold so strongly PPs support without any info from company, really impresive daylies charts how PPs hold the ground with 20 d SMA above 200 d SMA since GC occuredd. If this stock will run on any PR? Absolutely will and it will take out .0049 in the blink of a eye.
Good luck to all here
On 60 min charts Lower BB stands at $3.98 so great support at 4.00, there will be lots buyers lined up. I dont see this dip below $4.00 So place the Buy at 4.05-4.10 seems as ggood new entry so far. If we break $3.98 the on 60 min charts 50d SMA would be new support at 3.56. But that I doubt
Good luck
$3.94 solid support 30 min charts it will bounce of 50d SMA
G-Morning board CGFIA holding strong supporting levels, need PR very badly any PR will do.
Good luck
It will not drop until any FDA response very safe until then. Look at the daylies charts- "Overbought bullish", any other stock would already drop for consolidation
Good luck
Here we go, thanks didnt even know about that board.
Good luck to you
Feel sorry man. I called this a losser 3-4 months ago here but been called here a Basher :). How can you Bash a company with one Picture :)
Good luck to you with further market games
Absolutely I saw once a company to did it twice in one year and guess waht? The same players that lost even bought again and lost again. If you wanna make money on market Learn to play Options and give your self a time to do DD for any Game. OTCBB and Pink land is a Fantasy land remmember that.
Good luck
Acording to SEC regulation this is legal. Its up to investor to do his DD and make the desicion invest or not. Well if you thing about that when investors start to buy ARTS, what we were byuing here? A Picture? How ridiculous that sound hay. Well I made strong rule 3 years ago for me Never invest more then 100 bucs for any OTCBB or Pink company the rest playing only Nasdaq and stock around 5 bucs, less pain bigger reward. When I start trading I also did lot's mistakes put all money on one OTCBB stocks and waited or acumulated all year in the end "0" reward. I did repeat my mistakes untill I set my strong 100 bucs rule for any OTCBB stock and I dont care what potencial they have. Well what ARTS did today is actually Legal.
Good luck
Importante Number for today:
R3-5.49
R2-5.02
R1-4.69
PIVOT-4.22
S1-3.89
Heappy trading
This is a same song over and over on OTCBB, it never change, there always will be traders that will buy these nonsence worthles stocks and they will always do zero BID and R/S. For last ten years I trading always the same thing. OTCBB land 90% scam including Pink sheet.
This is the Push to 4.78 I was talking about in the AM.
Upper BB broken @ 4.38 next stop 4.50 and 4.78.
Cheers for today, will close very green $4.78 will be tested Gate to $5.00 bucs :)
Will end up green today will test FIBO R3-$4.78
and she's lunched 4.70 today
4.16 will shoot the PPs slowly back to upper BB-on 60 min to 4.38. Here she go
3.98 will place this right back to 4.10-3.70 nice support there. Looking good for today
Looks great Consolidation is over, nice work on the charts :)
Good luck
3.69 support next 3.17. I thing it will bounce back up from 3.70. 20D SMA on 60 min charts
wow 4.40 on pre. She's continue going up, would be realy nice to see today print $5.00
And I'm actually thing that the earnings will not effect EDAP at all at this stage FDA desicion is close? We will go up and test again yestrday highs 4.44-45
It wasn't the best, but I'm holding my shares for FDA. I thing it will work after all. Support @ 3.70 should hold. Charts Bullish and the trend is UP. Once we hit $5.00 dollars then train will really start going, Institusions will start buying EDAP.
Good luck
The earnings are not so good, might drop a bit, but I thing market is focusing on FDA, so it will support the PPs @ some point. GOD knows that Edap need that FDA decision
G-Morning board. Importante numbers for today:
R3-0.0036
R2-0.0031 (upper BB stand @ 0.0032 on daylies charts)
R1-0.0027
PIVOT-0.0022 (nice yestrday close on today Pivot)
S1-0.0018 (main support 0.0016)
Trend is bullish consolidation,I thing will see soon testing .0032 upper BB on daylies.
Heappy trading and Good luck
We all sure hope so :)
Good luck
isn't tommorow a 90 days since 8/19/2010? FDA suppose to give a decision
The double bottom is the reason I'm still holding. The risk is smaller VS profit all you need is keep stop exit @ .0015 anything above pure profit( depend where you entered or if you manage to avarage down)
But the outlook on charts is awsome - fundamentals that is another story.
Good luck